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ABSTRACT 
 
 
The Effect of Isoleucine Supplementation on Peripheral Blood Mononuclear Cell Metabolism in 
Subjects with Type 2 Diabetes 
 
 
Ellie Parker 
Department of Biomedical Sciences 
Texas A&M University 
 
 
Research Advisor: Dr. Traver Wright 
Department of Kinesiology 
Texas A&M University 
 
 
Type 2 diabetes (T2D) is an increasing health concern as 425 million people are 
diagnosed with it worldwide.  It is associated with chronic systemic inflammation and increased 
oxidative stress; individuals with these inflammatory conditions have altered metabolic pathways 
and mitochondrial function including changes in mitochondrial respiration values in peripheral 
blood mononuclear cells (PBMCs).  Mitochondrial respiratory capacity is vital to produce 
cellular energy in the form of adenosine triphosphate (ATP) via the tricarboxylic acid (TCA) 
cycle and mitochondrial electron transport chain (ETC).  Metabolic dysfunction associated with 
systemic inflammation can lead to limited production of tricarboxylic acid (TCA) cycle 
intermediates which are vital for metabolism.  It has previously been shown that providing 
anaplerotic TCA cycle precursors, specifically isoleucine and valine, can replenish TCA cycle 
intermediates.  The purpose of this study was to assess the mitochondrial function in PBMCs 
from eight control subjects and seven T2D subjects using high resolution respirometry.  Subjects 
with T2D received ten days of treatment with three grams daily of supplemental isoleucine.  
PBMC respiration was compared between control and T2D at baseline, and T2D subjects were 
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assessed for changes over the treatment duration.  Subjects with T2D had significantly lower 
leak respiration and leak-related coupling control ratio than healthy control subjects.  There was 
no significant change in measures of PBMC respiration from T2D subjects before and after 
treatment.  Although there appears to be minor differences in PBMC respiratory rate between 
subjects with T2D and healthy controls, 10 days of isoleucine supplementation was not effective 
at recovering altered PBMC respiration in T2D subjects. 
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NOMENCLATURE 
 
 
T2D               Type 2 Diabetes 
PBMC            Peripheral Blood Mononuclear Cells 
ATP            Adenosine triphosphate 
TCA            Tricarboxylic acid 
ETC             Electron transport chain 
BCAA  Branched chain amino acid  
ONS  Oral nutritional supplement  
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CHAPTER I 
INTRODUCTION 
 
 
T2D Background 
Type 2 diabetes (T2D) is a leading health concern in the United States, affecting about 
9.4% of Americans (Division of Diabetes Translation At A Glance | CDC, 2019).  T2D is a 
metabolic disorder resulting in hyperinsulinemia and hyperglycemia and characterized by insulin 
resistance in tissues including liver, skeletal muscle, and adipocytes (Hameed et al. 2015).  If left 
unmanaged, diabetics are at greater risk of other health problems including nonalcoholic fatty 
liver disease, kidney disease, and cardiovascular disease (Piette and Kerr 2006).  The primary 
strategy to manage T2D is to incorporate healthy eating habits in conjunction with physical 
activity to lower blood sugar levels to reverse the development of chronic complications 
associated with diabetes.  In addition to diet and exercise, pharmacological interventions include 
antidiabetic medication and insulin therapy (Polonsky and Henry 2016).  Examples of 
medications include those that work to lower blood sugar, often by improving cell sensitivity to 
insulin (Polonsky and Henry 2016).  With proper management, subjects with T2D can maintain 
blood glucose within a normal range (Polonsky and Henry 2016).  Because so many Americans 
are affected by T2D, research into alternative strategies to manage diabetes has the potential to 
have a large impact.    
Metabolic Mechanisms 
 Metabolism is the overarching process of utilizing food and nutrient intake to be 
converted into energy and encompasses all catabolic and anabolic reactions in the body 
(Mailloux et al. 2007).  Metabolic pathways are often controlled by activating or inhibiting 
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regulatory enzymes to determine the reaction rate.  The activation or inactivation of certain 
enzymes is also regulated via compartmentalization, meaning that certain reactions occur in 
specific organelles (Metallo and Vander Heiden 2013).  Metabolic pathways regulating the 
conversion of chemical energy into useful energy are regulated via a series of intermediate 
reactions (Metallo and Vander Heiden 2013).  The energy used to fuel these pathways is 
generated by the metabolic breakdown of carbohydrates, lipids, and proteins (Hardie 2012).  
Metabolic breakdown of these fuels for energy converges at the tricarboxylic acid (TCA) cycle 
within the mitochondria (Mailloux et al. 2007).  The TCA cycle converges with the electron 
transport chain (ETC) to generate energy in the form of adenosine triphosphate (ATP) (Mailloux 
et al. 2007).  Ultimately the body’s physiological processes are concerned with maintaining 
homeostasis and ensuring that the body has enough energy to function effectively.  Metabolic 
mechanisms carry this out and demonstrate the requirement of properly functioning metabolism.  
Mitochondria’s Role in Energy Capacity 
In previous studies it has been determined that insulin resistance is associated with 
mitochondrial dysfunction in muscle tissue (Larsen et al., 2009).  In muscle tissue, it has been 
demonstrated that the total volume of the mitochondria in the muscle is directly proportional to 
the oxidative capacity.  Mitochondrial dysfunction has been linked inherited human disorders 
and is common in diseases such as cancer, obesity, and neurodegenerative disorders (Nunnari & 
Suomalainen, 2012). 
 Mitochondria are present in almost all eukaryotic cells and are responsible for a variety of 
important cellular processes such as energy production, calcium homeostasis, phospholipid 
synthesis, cell cycle control, and cell death (Osellame et al. 2012).  The coordination of the 
necessary intermediaries allow for proper functioning of the mitochondrial respiratory chain.  
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The main driver in aerobic mitochondrial metabolism is the proton gradient (Schroeder et al. 
2009).  The TCA cycle makes NADH and FADH2, which carry electrons to the inner 
mitochondrial membrane (Martinez-Reyes and Chandel 2020).  These carriers release the 
protons and electrons to a series of proteins on the inner mitochondrial membrane that utilize the 
energy from the transfer of electrons to drive the proton motive force in the ETC (Martinex-
Reyes and Chandel 2020).  After arrival at the inner mitochondrial membrane, the electrons are 
accepted by ETC protein complexes I and II and are used to pump protons into the 
intermembrane space, creating a potential difference between the matrix and intermembrane 
space (Martinex-Reyes and Chandel 2020).  This proton gradient is what ultimately powers the 
generation of the majority of aerobic ATP production.  The proton gradient favoring flux of 
proteins back to the interior of the matrix is used to power ATP synthesis (Schroeder et al. 2009).   
 The proper functioning of the TCA cycle is important for both energy production as well 
as for biosynthesis of precursors for other metabolic pathways.  If TCA cycle intermediates are 
removed as precursors for biosynthesis, the cycle is not able to function unless the intermediates 
are replenished by anaplerosis.  Depletion of metabolic intermediates can result in disruption of 
metabolism and oxidative stress due in part by leakage of electrons directly to oxygen subverting 
the ETC.  This oxidative stress can eventually lead to cellular damage and necrotic cell death 
(Zhao et al. 2019).  As the primary driver of aerobic metabolism, mitochondria are of vital 
importance to maintaining cellular homeostasis, energy production, and biosynthetic needs.  
Inflammation and Metabolism in T2D  
 T2D is characterized by inflammation, hyperglycemia, insulin resistance, as well as other 
factors (van Greevenbroek et al. 2013).  The inflammatory markers associated with T2D are seen 
by pro-inflammatory cytokine production and amplified by adipokines (Tsalamandris et al., 
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2019).  The immune system is activated with the incidence of T2D in adipose tissue 
inflammation (Tsalamandris et al., 2019).  Ongoing inflammation resulting from an immune 
response leads to changes in metabolic activity (Kominsky et al., 2010).  These changes in 
metabolic activity include depletion of nutrients, increased oxygen consumption, and increased 
production of nitrogen intermediates (Kominsky et al., 2010).  All of the aforementioned results 
occur due to the recruitment of inflammatory cells, primarily monocytes and neutrophils 
(Kominsky et al., 2010).  The action of monocytes is part of the adaptive immune response when 
the cells are recruited to inflammation sites (Kominsky et al., 2010).   
The corresponding cell migration to the inflammatory site requires energy.  At the site of 
inflammation, the nutrient, energy, and oxygen demands are increased in order to carry out these 
actions (Kominsky et al., 2010).  Sites with chronic immune responses and inflammation become 
depleted of their nutrients, energy, and oxygen, paralleling physiological hypoxia and decreased 
metabolic efficiency (Kominsky et al., 2010).  Insulin resistance occurs with lessened insulin 
sensitivity in target cells (van Greevenbroek et al., 2013).  Insulin resistance parallels decreased 
metabolic control and increased lipid and glucose concentration.  In both the liver and muscle, 
this ultimately results in insulin resistance (Muoio & Newgard, 2008).  In the muscle, this means 
that lipid-derived intermediates will accumulate in the mitochondria to yield both mitochondrial 
stress and insulin resistance (Muoio & Newgard, 2008).   
Cellular stress occurs physiologically in response to a stressor (Mechanik, 2006).  The 
TCA’s cycle limited ability to compensate for this cellular stress leads to decreased oxidative 
phosphorylation capacity and less ETC activity, characteristic of mitochondrial insufficiencies.  
The overall stress response in subjects with T2D diverts metabolic fuel from anabolic functions.  
To provide for the inflammatory response, tissue catabolism increases to provide the amino acids 
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necessary for protein synthesis.  These pro-inflammatory effects of hyperglycemia are related to 
reactive oxygen species (ROS) and cytokines specifically (Mechanick, 2006).  As this discussion 
documents, T2D negatively impacts the function of metabolic mechanisms by having to 
prioritize the most necessary physiological functions for the body. 
Mitochondria and This Study 
Mitochondrial respiratory capacity is a measure of mitochondrial oxygen consumption to 
produce cellular energy in the form of ATP via the TCA cycle and mitochondrial ETC. The TCA 
cycle is necessary for energy production and aerobic respiration (Schroeder et al. 2009). 
Metabolic dysfunction associated with systemic inflammation can lead to limited production of 
TCA cycle intermediates which are vital for metabolism (Green et al. 2016).  It has previously 
been shown that providing TCA cycle precursors, specifically isoleucine and valine, can 
replenish succinyl Co-A in the TCA cycle (Green et al. 2016).  The branched-chain amino acids 
(BCAAs) consist of isoleucine, valine, and leucine.  The BCAA isoleucine was used in this study 
because evidence from non-obese diabetic mice has consistently demonstrated that aromatic 
amino acids and BCAAs are two of the most significantly impacted pathways to improve 
inflammatory symptoms (Liu et al. 2017).  BCAAs are used rather than aromatic amino acids 
because supplementation of BCAAs is thought to promote anabolic pathways (Holeček 2018). 
This research assessed metabolism in peripheral blood mononuclear cells (PBMCs) in 
subjects with T2D and age matched controls.  Individuals with these inflammatory conditions 
have altered metabolic pathways and mitochondrial function including changes in respiration 
values of PBMCs (Roe and Mochel 2006).  The objective of this study was to determine whether 
an isoleucine supplement would promote the TCA cycle to combat insulin resistance and the 
metabolic mechanisms responsible for this disparity.  In the current study we assessed 
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mitochondrial respiration in PBMCs of subjects with T2D using an Oroboros O2k (Oroboros 
Instruments; Innsbruck, Austria) for high resolution respirometry.  PBMCs offer a minimally 
invasive way to measure cellular respiration using a simple blood draw (Hedges et al. 2019).  In 
this study, subjects with T2D consumed an isoleucine supplement and were assessed at baseline 
and again immediately following 10 days of treatment.  This served to assess the role of an 
isoleucine supplement in alleviating inflammation and oxidative cellular stress.   
This research could lead to a novel and potentially effective way to provide a nutritional 
intervention for subjects with T2D.  The efficacy of the cell’s current activity and mitochondrial 
function is directly correlated to its ability to produce energy in the form of ATP.  Because of 
this, treatment may potentially serve to improve the function of their mitochondria, thereby 
providing for increased ETC functionality, and leading to increased oxidative capacity.     
Benefits of a Nutritional Intervention 
A plethora of medications are available for and administered to subjects with T2D; in 
conjunction with these, subjects are typically also given advice on how to alter their diet.  An 
oral nutritional supplement (ONS) is a supplementation to normal dietary food specifically for 
medical purposes, and ONS in conjunction with dietary advice have been shown to be more 
effective than dietary advice alone (Baldwin and Weekes 2011).  Whereas typical T2D 
medications address specific symptoms of diabetes such as blood pressure and blood sugar, a 
nutritional intervention affects the subject’s metabolism at the cellular level.  By administering a 
supplement to the subject rather than simply giving dietary advice, one can have increased 
assurance that the treatment is implemented.  Amino acids in particular allow for the body to 
obtain the levels it needs to continue proper functioning (Odia & Esezobor, 2017).  The ultimate 
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goal of the study was to facilitate an effective and implementable intervention for subjects with 
T2D. 
Isoleucine is classified as an essential amino acid, meaning that it must be obtained by the 
diet because the body is unable to synthesize it (Holeček 2018).  In addition, isoleucine is a 
hydrophobic amino acid, meaning that it can pass through the cell’s plasma membrane and enter 
the cell, allowing it to affect greater change (Brosnan and Brosnan 2006).  It has previously been 
suggested that supplementation of BCAAs may help to improve the repair of damaged muscle 
(Monirujjaman and Ferdouse 2014).  Amino acids, including isoleucine, are classified as 
hydrosylates, meaning that they exhibit antioxidant properties (Dash and Gosh 2017).  This is 
vital in combatting the oxidative stress that can result in subjects with T2D (Dash and Gosh 
2017).  Importantly, BCAAs promote muscle cell metabolism and glucose uptake by the liver, 
giving them the potential to decrease the high blood glucose present in T2D subjects 
(Monirujjaman and Ferdouse 2014).  
Peripheral Blood Mononuclear Cells 
 PBMCs are classified as a peripheral blood cell with a round nucleus (Navas et al. 2019).  
Examples of these include lymphocytes and monocytes, which are involved in the immune 
system and immune response (Navas et al. 2019).  PBMC respiration is a marker of 
inflammatory conditions (Kleiveland, 2018).  The subject’s physiological status includes 
hormone levels, nutritional status, and inflammation, which affect the PBMC composition 
(Kleiveland, 2018). 
Study Overview 
The BCAA administered to subjects with T2D in this study was isoleucine.  Blood was 
collected and PBMCs isolated from control and T2D subjects to measure mitochondrial function.  
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PBMCs were separated from whole blood using centrifugal separation with density gradient 
media.  Cell counts were done using a hemocytometer to provide a means for determining 
relative oxygen consumption.  Using an Oroboros O2K oxygraph, substrates, uncouplers, and 
inhibitors were added by stepwise titration into the oxygraphy resolution respirometry chamber 
to determine PBMC respiration at various respiratory states.  These respiratory states include 
leak respiratory capacity, maximum coupled oxidative phosphorylation (OXPHOS), and 
uncoupled maximal electron transport system respiratory capacity.  Detailed analysis of the high 
resolution respirometry results was useful to show how isoleucine supplementation affected 
PBMC cellular respiration in T2D.  The knowledge gathered from the effect of isoleucine on 
T2D subjects will serve as a basis for further nutritional and supplemental interventions for T2D 
and other inflammatory conditions. 
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CHAPTER II 
METHODS 
 
 
Study Inclusion Criteria 
To be included in this study, subjects had to be between 45 and 84 years of age with a 
body mass index (BMI) greater than or equal to 28 kg/ m2, a stable body weight that maintained 
a range within five percent of their baseline weight over the last three months, and a physical 
exam, medical history, and lab screening that indicated that the subject was of suitable health. 
The subject had to be able to independently walk, stand, and sit down, lie down for up to 10 
hours at a time, and was able and willing to follow the experiment protocol.  T2D subjects had to 
be clinically diagnosed and currently taking insulin or an oral medication to lower their glucose.  
Data from seven subjects with T2D and eight healthy control subjects are included in this study. 
Treatment 
T2D, characterized by insulin resistance, is associated with chronic systemic 
inflammation and increased oxidative stress, ultimately leading to mitochondrial dysfunction 
(Vikram et al. 2014).  In the current study we assessed mitochondrial respiration in PBMCs of 
subjects with T2D using an Oroboros O2k (Oroboros Instruments; Innsbruck, Austria) for high 
resolution respirometry.  PBMCs offered a minimally invasive way to measure cellular 
respiration using a simple blood draw.  
In this study, subjects with T2D consumed a supplement of three g isoleucine a day for 
10 days. Subjects were assessed at baseline and again immediately following 10 days of 
treatment.  This study assessed the efficacy of a simple isoleucine nutritional supplement to 
alleviate cellular stress, inflammation, and metabolic disturbances resulting from mitochondrial 
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dysfunction associated with T2D.  In addition to samples being collected from subjects with 
T2D, blood samples were also collected from control subjects without T2D to allow for the 
differences in their mitochondrial oxygen consumption to be analyzed.  The age matched healthy 
control subjects had only baseline experimental data because they were not administered a 
treatment. 
PBMC Isolation 
Blood was collected from subjects with T2D and PBMCs were isolated using centrifugal 
separation with density gradient media. This was done by first mixing the 10 mL blood sample 
with 10 mL of phosphate-buffered saline (PBS) (BIORAD, 1610780) and layering this dilution 
on top of 15 mL Ficoll (GE Healthcare).  Ficoll is a highly branched high-mass hydrophilic 
polysaccharide that dissolves readily in aqueous solutions.  This was centrifuged at 1000 G for 
30 minutes with no acceleration or deceleration to yield density-based separation (Fig. 1).  The 
cloudy PBMC layer was transferred to a new tube and diluted with approximately 7 mL of PBS, 
then centrifuged at 250 G for 10 minutes at 20 °C.  The resulting cellular pellet was then 
resuspended in 5 mL Mir05 and 2.4 mL of the sample was transferred to each O2K chamber for 
high resolution respirometry.  100 µL was sub-sampled from each chamber into a tube with 400 
µL of .4% trypan blue and inverted to mix.  This was used for cell counts after the mixture had 
5-15 minutes to stain the cells.   
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Figure 1: PBMC Isolation.  Seperation of the different parts of blood using centrifugal 
separation.  The left image shows the top red layer consisting of blood mixed with PBS carefully 
layered above the Ficoll.  The right image is the result after centrifuging, when the different 
layers separate based on their relative densities. 
 
Cell Count 
Cell counts were done using a hemocytometer to provide a means for determining 
relative oxygen consumption. 12 µL of the above cell mixture was pipetted into one side of the 
hemocytometer grid and counted using a microscope.  Cell density in million cells/ mL was 
calculated by averaging the viable cell count from each of the four grids and multiplied by 
50,000 to correct the volume of 1/10,000 mL per grid and the 1:5 stain dilution.   
High Resolution Respirometry 
High Resolution Respirometry was performed using an Oxygraph-2K (O2K) 
respirometer (Oroboros Instruments, Innsbruck, Austria), and data was collected by a computer 
using DatLab software (Oroboros Instruments, Innsbruck, Austria).  Before the substrate, 
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uncoupler, and inhibitor (SUIT) protocol began, the oxygen electrode was calibrated.  After 
oxygen calibration, the cell samples were inputted into the chamber and the stopper was used to 
partially seal the chamber.  Oxygen was injected into the chamber and the oxygen concentration 
was tracked so that once the oxygen buffer concentration reached 400 nmol/ml, the chamber was 
fully sealed to force the remaining gas out.  Throughout the protocol, oxygen concentration was 
maintained between 250 and 400 nmol/ml.  Once the oxygen concentration stabilized, respiratory 
flux baseline was established in the absence of metabolic precursors.  The SUIT protocol, 
stepwise titration of substrates, adenylates, and inhibitors was used to establish specific 
respiratory states (Table 1).  For each metabolic state, a new steady state was established before 
the titrations for the next metabolic state could be performed. 
Table 1: SUIT protocol was administered with stepwise titration of substrates, adenylates, and 
inhibitors to achieve the following PBMC respiratory states: permeabolized, leak, OXPHOS, 
Electron Transport System (ETS), and complexes I, II, and IV.  This table demonstrates the 
cellular state each substrate, adenylate, and inhibitor was administered to facilitate. 
 
Respiratory State Solution 
Routine PBMCs in MiR05 
Permeabolized Digitonin 
Leak Pyruvate 
Malate 
CI ADP 
OXPHOS Glutamate 
Succinate 
ETS CCCP 
CII Rotenone 
No respiration Antimycin A 
CIV Ascorbate 
TMPD 
Inhibit CIV Azide 
17 
The reagent concentrations used in this SUIT protocol were: 8.1 µM digitonin, 5 mM 
pyruvate, 1 mM malate, 1.75 mM ADP, 5 mM glutamate, 10 mM succinate, 0.5 µM CCCP,1.5 
µM rotenone, 1.875 µM antimycin A, 2 mM ascorbate, 0.3 mM TMPD, and 10 mM azide.  The 
respiratory states initiated by these protocols include: routine, permeabolized, leak, OXPHOS, 
and ETS.   
Routine Respiration represents the untreated baseline respiratory rate, and is initiated by 
equilibrating PBMCs in MIRO5 buffer to temperature and determining respiratory rate in 
unaltered conditions.   
Permeabolized respiratory capacity was then induced by titrating the permeabolizing 
agent digitonin resulting in washing substrates and adenylates out of the cell.  This respiratory 
state sets the stage for stepwise reintroduction of specific substrates.    
Leak respiration was induced by reintroducing the substrates pyruvate and malate for 
electron influx through complex I, but without adenylates to allow ATP synthase activity to 
determine maximum uncoupled respiratory capacity. 
CI respiration was induced with addition of the adenylate ADP to allow ATP synthase 
activity and maximize the respiratory flux through complex I. 
OXPHOS respiration was induced with addition of glutamate and succinate to provide 
substrates for complex II.  OXPHOS represents the cell operating at maximum respiratory 
capacity with mitochondrial oxidative phosphorylation coupled with ATP synthase and native 
uncoupled leak respiration.   
Electron Transport System (ETS) respiratory rate was induced with the uncoupler CCCP 
to artificially elevate the proton leak and determine the cell’s oxidative capacity beyond 
OXPHOS. 
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CII respiration was induced with addition of rotenone, a complex I inhibitor, to represent 
the maximum respiratory capacity driven by complex II.  
No respiration was induced by the inhibitor antimycin, because it represses cellular 
respiration.  This gives the baseline respiratory flux that the other values are corrected for. 
CIV was induced with ascorbate and TMPD.  These reducing agents subvert the TCA 
cycle and provide direct maximal electron transfer to maximize ETS flux.  Complex IV was then 
inhibited with azide, and the difference between these two values provides the flux contribution 
of complex IV.   
These respiratory states are shown for the described high resolution respirometry SUIT 
protocol (Fig. 2).  In addition to each of the steady state respiratory rates, respiratory ratios were 
calculated to determine relative respiratory capacity for various respiratory states.  To assess 
complexes I and II’s respective contributions to total OXPHOS capacity, the substrate control 
ratio (SCR) was determined: SCRCI = CI / OXPHOS and SCRCII = CII / OXPHOS.  To 
determine the relative contribution of leak respiration to total OXPHOS respiration, the coupling 
control ratio was calculated (CCR = LEAK / OXPHOS).  Finally, the respiratory control ratio 
was calculated to characterize the mitochondrial ETS respiratory reserved capacity that exceeds 
the OXPHOS capacity (RCR = OXPHOS / ETS).   
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Figure 2: High resolution respirometry.  Example run after employing the SUIT protocol shows 
the oxygen consumption and oxygen flow in each of the cellular states. 
 
Data Analysis 
Data was analyzed using GraphPad Prism 5 (Graph Pad Software, Inc., San Diego, CA) 
and expressed as the mean and standard deviation.  Comparisons between the healthy control and 
pre-treatment T2D was measured using a t-test with a significance threshold of p < 0.05.  
Comparisons between pre and post-treatment measures were assessed using paired t-tests with a 
significance threshold of p < 0.05.  Due to requirements limiting processing time, each sample 
was run redundantly in two separate chambers.  Chamber A was used for analysis by default 
unless there was an insufficient cell count, operator error, or hardware error that required 
alternative use of chamber B.   
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CHAPTER III 
RESULTS 
 
 
We measured PBMC respiratory rates in various respiratory states for healthy control 
subjects and subjects with T2D both before and after treatment.  The initial measure of routine 
respiration represented the baseline respiratory rate of unaltered PBMC cells introduced into 
respiratory buffer.  After permeabolization, the respiratory rate decreased to low levels due to the 
washing out of substrates and adenylates in preparation of stepwise reintroduction of substrates 
and adenylates (Fig. 3).  Reintroduction of substrates to induce leak respiration resulted in 
negligible increase in respiration, indicating low levels of PBMC leak respiration.  The addition 
of the adenylate ADP allows for additional proton flux through ATP synthase, which increased 
the respiratory rate.  The addition of the substrates glutamate and succinate provided the 
substrates for complex II and resulted in increased respiratory rate (Fig. 3).  Artificially induced 
leak respiration with the uncoupler CCCP resulted in negligible change in respiration.  The 
inhibition of electron flux through complex I with rotenone leaves only electron flux through 
complex II to support oxidative phosphorylation.  The introduction of ascorbate and TMPD 
provide reducing agents to subvert the TCA cycle and maximize ETS flux.  The difference 
between this value and complex IV inhibited with azide provides complex IV’s flux contribution 
(Fig. 3). 
There was a trend for the routine respiratory rate to be higher in the control than in the 
T2D, but it did not reach statistical significance (p = .094; Fig. 3).  Leak respiration was 
significantly higher for control compared to pre-treatment T2D (p = .009; Fig. 3).  There was no 
difference between control and T2D in the permeabolized, complex I, OXPHOS, ETS, complex 
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II, or complex IV respiratory states.   From pre to post-treatment, there were no significant 
changes in any of the respiratory states in the subjects given this isoleucine supplement for ten 
days. 
 
Figure 3: Respiratory Rates.  Oxygen flow per cell in the Routine, permeabilized, leak and 
oxidative phosphorylation states.  Relative oxygen flux measured using high resolution 
respirometry.  Average rates were taken from controls and T2D subjects before and after three 
grams of isoleucine supplementation for 10 days. 
 
Coupling control ratio (CCR) was significantly greater in control subjects than T2D (p = 
.027; Fig. 4).  Neither substrate control ratio (SCR) nor respiratory control ratio (RCR) were 
significantly different between the control and T2D.  None of these respiratory ratios changed 
significantly with isoleucine treatment for T2D subjects (Fig. 4).  The only significant difference 
detected included greater leak respiration and coupling control ratio in the control compared to 
T2D (Figs. 3 and 4).   
* 
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Figure 4: Respiratory Ratios.  Controls and T2D subjects before and after treatment, respectively.  
These values were not measured in oxygen flow per cell, but are measured in a ratio instead.  
The respiratory ratios were calculated from the respiratory rate values.  SCRCI = CI / OXPHOS 
and SCRCII = CII / OXPHOS.  CCR = LEAK / OXPHOS.  RCR = OXPHOS / ETS.  Average 
rates were taken from controls and T2D subjects before and after three grams of isoleucine 
supplementation for 10 days.    
  
  
* 
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CHAPTER IV 
DISCUSSION 
 
Respiratory States 
            After PBMCs were introduced and equilibrated to temperature and pressure in the high 
resolution respirometry chamber, they established native steady state routine respiratory rates 
assisted by intracellular substrates.  After permeabolization with digitonin, substrates and 
adenylates used to support cellular respiration were washed out of the cell resulting in decreased 
respiration (Fig. 3).  With induced leak through the reintroduction of the substrates pyruvate and 
malate, there was no detectable change in the respiratory rate from the permeabolized state.  In 
the leak state, there are no adenylates for proton flux through ATP synthase, leaving leak as the 
only source of proton flux back to the matrix.  Leak level is low, indicating that leak is not a 
significant portion of respiration in PBMCs.  To induce maximum complex I respiration, the 
adenylate ADP was added to allow for proton flux through ATP synthase, resulting in increased 
respiratory rate.  Glutamate and succinate were introduced to support electron flux through 
complex II, which induces maximum OXPHOS respiration with electron flux through complexes 
I and II, proton flux through ATP synthase, and uncoupled leak respiration.  ETS respiration was 
induced to artificially increase the leak by creating an additional place for electrons to filter 
through, elevating the proton flux.  ETS respiration did not increase past the level of OXPHOS, 
indicating that the ETC of PBMCs is efficient since it did not have the capacity for higher 
respiration past OXPHOS (Fig. 3).   
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Control vs. T2D and Treatment 
The goal of this experiment was to determine if isoleucine was an effective treatment for 
the PBMC mitochondrial dysfunction in subjects with T2D.  Based on previous research 
conducted with other inflammatory conditions, it was hypothesized that isoleucine may improve 
mitochondrial function in subjects with T2D.  Leak respiration made up a minor portion of 
OXPHOS in the calculated CCR value, suggesting that leak is not a significant portion of 
respiration in PBMCs (Figs. 3 and 4).  Although it was a minor portion of overall respiratory 
capacity, PBMC leak respiration and CCR were both significantly greater in healthy control than 
T2D subjects.  These measures are related to each other in that CCR uses the leak respiratory rate 
to calculate its final value.  Leak respiration is thought to reduce the production of reactive 
oxygen species and subsequent cellular damage (Zorov et al. 2014).  Leak respiration in PBMCs 
from control subjects was higher compared to T2D, and thus control subjects may be more 
capable of regulating reactive oxygen species production (Fig. 3).  While these differences 
showed up as significant, this trend may not necessarily hold with a larger sample population.  
However, our protocols proved to be effective with high repeatability in respiratory measures.  
It was apparent that this specific treatment of isoleucine supplementation did not alter 
PBMC respiratory rates in subjects with T2D. In examining potential direction forward with this 
experiment, it is important to understand why this treatment could potentially alter PBMC 
respiration.  A favorable result would improve oxygen flow in T2D subjects with administration 
of the isoleucine supplement.  If a successful outcome were to take place, indicating a 
statistically significant difference in the respiratory rates between the pre and post-treatment in 
T2D subjects, this would mean that the oxidative capacity had increased.  Oxidative capacity is 
known to increase with exercise and is correlated with a greater number of mitochondrial 
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proteins being expressed (Irving et al., 2015).  Exercise capacity is a predictive indicator of 
metabolic health and coincides with low blood pressure and greater insulin sensitivity (Overmyer 
et al., 2015).  With these effects, it can be determined that greater oxidative capacity is indicative 
of a more efficient functioning metabolism.  Since chronic systemic inflammation is one of the 
primary characteristics of T2D that correlates with less efficient metabolic processes, it can be 
concluded that greater oxidative capacity parallels reduced inflammation.  So, if this treatment 
had yielded increased oxidative capacity with the post-T2D group, it would indicate that the 
isoleucine supplement positively impacted the metabolism in these subjects (March et al., 2002).  
Succinyl-CoA in the TCA cycle is derived from isoleucine (March et al., 2002).  In this 
anaplerotic role, isoleucine provides the necessary precursor biomolecules for succinyl-CoA to 
further the TCA cycle.  This in turn provides electron flux to the ETC, with the ultimate goal of 
generating energy and yielding increased oxidative capacity. 
Study Limitations 
 A variety of limitations may have affected this research including small sample size.  The 
initial period of sample collection was used to develop experimental methodology and refine the 
experimental techniques and procedures to produce more accurate and consistent results.  As 
such, the first five subjects were not included in the data analysis, leading to lower statistical 
power.  Interruption in the supply of metabolic tracers used in other aspects of this study resulted 
in an unforeseen pause in new subject recruitment and limited the sample size of these 
preliminary results.  An additional source of potential error is related to potential RBC 
contamination in the isolated mononuclear cells because this would artificially inflate the cell 
count.  A cell count that is higher than reality would correspond to a higher expected oxidative 
capacity.  This would parallel a seemingly low respiratory rate because the true cell count is 
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lower, meaning there are less cells with the capability to facilitate mitochondrial respiration.  
Another limitation was that the subjects were home when they were taking the supplement.  
Because of this, there was no true way of knowing whether or not they took the supplement as 
directed because their compliance and follow through was self-reported. 
Next Steps 
The presented results are preliminary from ongoing research and motivate multiple next 
steps to expand and further the effective scope of this research.  The PBMCs measured as a 
marker for T2D mitochondrial function in this study are only one marker of this disease.  
Although isoleucine supplementation did not alter respiratory capacity in PBMCs, these results 
do not indicate that mitochondrial function was not affected in other tissues.  While PBMCs were 
used to analyze oxidative capacity because of their minimal invasiveness, it may be beneficial to 
conduct a muscle biopsy to assess skeletal muscle mitochondrial function.  This would allow for 
determination of whether isoleucine’s effects are insignificant only in the PBMC measure 
analyzed in this study, or if these affects are true of overall physiological function.  To further 
verify these results, it would be interesting to assess the measures of the subjects’ blood glucose 
levels, blood pressure, or other indications of T2D.  These values were taken, but as a part of a 
different study.  This would allow for the assessment of the treatment’s effect on the cellular 
oxidative levels, from the PBMC study we conducted, and also the disease symptoms that 
current T2D address.   
In addition, isoleucine is one branched chain amino acid, a part of the overarching group 
that has been shown to positively affect mitochondrial function in other chronic inflammatory 
conditions.  It might be productive to conduct a similar study with other BCAAs including valine 
and leucine.  A proposed future step is to look at the effects of valine because, compared to 
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leucine, valine’s structure varies more from that of isoleucine.  If valine were to induce a 
significant change in the respiratory capacity, this would provide data about effective nutritional 
supplement interventions for T2D.  Another proposed future research study would involve 
conducting the study for a longer duration.  Although 10 days of isoleucine supplementation did 
not alter PBMC respiration in subjects with T2D, longer duration supplementation may be 
required to invoke change. 
Conclusion 
We were able to develop protocols to collect consistent and repeatable HRR measures in 
isolated PBMC from whole blood.  PBMC leak respiration and CCR were both significantly 
greater in control than T2D subjects.  However, isoleucine treatment did not alter the respiratory 
rates to be more similar to control measures. 
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